Thriving Future Ahead: Europe Viscosupplementation Market Predicted to Grow at 9.37% CAGR through 2032

Europe Viscosupplementation Market was worth US$ 4.5 Billion in the year 2022 and is expected to cross US$ 11 Billion by the year 2032 at a CAGR of 9.37% between 2022 and 2032.

European guidelines state that viscosupplementation products are categorized as ‘Class III’ type; which implies – a medical device that does incorporate medical substance as one of the integral parts wherein the action of medical substance turns out to be ancillary. The category is amongst the high risk categories and there is a need for premarket approval on this count. Technical performance and safety are the parameters to be looked into. Limited data suffices; which is inclusive of laboratory testing, literature review, and petite clinical trials. Notified bodies need to approve. They could be inclusive of private organizations that EFTA countries recognize. As such, the product gets licensed to be used all through the EU.

It needs to be noted that side effects get reported only to notified bodies and not to any of the government bodies.

Identify key trends, drivers, and challenges in the market, which will help vendors improve their strategies to stay ahead of their competitors. View our PDF Sample Report https://www.futuremarketinsights.com/reports/sample/rep-EU-1383

Viscosupplementation is carried out on outpatient basis. It has a low recovery time; which does render it one of the best fits for those who wish to resume work at the earliest. This procedure proves to be convenient for youngsters as well as elderly people as it makes use of single-injection treatments.

As of now, the market is witnessing saturation with several categories of the HA (Hyaluronic Acid)-based products with alterations in molecular weight. The products in pipeline include combination of pain-relieving effect on the part of corticosteroids with HA’s long lasting effect lasting for close to 6 months. HA-based intra-articular injections do help in restoration of usual viscoelastic properties of the altered synovial fluid inside the knee joint; thereby rendering therapeutic effect.

Extensive research is being conducted with regards to Europe viscosupplementation and the outcome is being incorporated. This is evident from the fact that Researchers based out of Humboldt-Universitat zu Berlin, along with Berlin Institute of Health (Germany), did report that HA is capable of influencing cartilage metabolism through upregulation of metalloproteinase inhibitor 3 in OA-like situation.

Europe is witnessing an exorbitant increase in number of the patients contracting osteoarthritis; who are looking out for alternatives to knee replacement due to side-effects linked with corticosteroid injections and NSAID.

Competitive Viscosupplementation

• Fidia Farmaceutici S.p.A., in December 2019, came up with TRILURON (containing sodium hyluronate). It’s a HA-based intra-articular viscosupplement meant to treat knee OA.
• Anika Therapeutics, Inc., in November 2019, took part in MEDICA 2019 International Trade Fair (Germany) and the International Cartilage Regeneration and Joint Preservation Society Focus Meeting (Austria).

Are you looking for customized information related to the latest trends, drivers, and challenges? Speak to Our Analyst@ https://www.futuremarketinsights.com/ask-question/rep-EU-1383

What does the Report enclose?

• The research study is based on product type (single injection viscosupplementation, three injection viscosupplementation, and five injection viscosupplementation), by end-user (hospitals, Ambulatory Surgical Centres, and orthopedic clinics), and by key regions/countries (Western Europe (UK, France, Germany, Spain, Italy, Nordics, and Rest of Western Europe), and Eastern Europe (Russia and Rest of Eastern Europe)).
• With growing incidences of osteoarthritis, Europe Viscosupplementation market is expected to grow unstoppably in the forecast period.

Key Players

Some key players in the global infusion pumps market identified in this report are Anika Therapeutics Inc., Sanofi S.A., Zimmer Biomet Holdings, Meda AB, Ferring B.V, Fidia Pharmaceutici S.p.A, and Bioventus LLC. The report also identifies company-specific strategies related to product development, market consolidation initiatives and analysis of their specific strengths, weaknesses, opportunities and threats.

Grow your profit margin with Future Market Insights – Buy the report@ https://www.futuremarketinsights.com/checkout/1383

Key Segments

• Product Type
  • Single Injection Viscosupplementation
  • Three Injection Viscosupplementation
  • Five Injection Viscosupplementation
• End User
  • Hospitals
  • Ambulatory Surgical Centres
  • Orthopaedic Clinics

About FMI:

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs